ea0070aep654 | Pituitary and Neuroendocrinology | ECE2020
Munoz Diego
, Carlos Percovich Hualpa Juan
, Weber Bettina
, Atencia Goñi José
, González Fernández Laura
, Miguélez González María
, Brox Torrecilla Noemí
, José Añez Ramos Roberto
, Maricel Rivas Montenegro Alejandra
, López Guerra Aurelio
, Lucía Olmedilla Isishi Yoko
, Ángeles Vélez Romero María
, Ágreda García Javier
, Picallo Pérez María
, Monereo Megías Susana
, García Centeno Rogelio
Introduction: Lutetium-177-DOTATATE (Lu177) is approved in patients with well-differentiated (G1 and G2) neuroendocrine tumors (NETs) positive to somatostatin receptors, progressive and unresectable or metastatic. Lu177 has been shown to increase progression-free survival and the quality of life of these patients.Material and Methods: Retrospective descriptive study of a series of 15 cases with NETs treated with Lu177. Demographic data, tumor characteris...